On the recordJuly 11, 2024
Madam President, I further ask that the Cornyn substitute amendment at the desk be considered and agreed to; that the bill, as amended, be considered read a third time and passed; and that the motion to reconsider be considered made and laid upon the table with no intervening action or debate. The PRESIDING OFFICER. Without objection, it is so ordered. The amendment (No. 2399) in the nature of a substitute was agreed to, as follows: (Purpose: In the nature of a substitute) Strike all after the enacting clause and insert the following: SECTION 1. SHORT TITLE. This Act may be cited as the ``Affordable Prescriptions for Patients Act of 2023''. SEC. 2. TITLE 35 AMENDMENTS. (a) In General.--Section 271(e) of title 35, United States Code, is amended-- (1) in paragraph (2)(C), in the flush text following clause (ii), by adding at the end the following: ``With respect to a submission described in clause (ii), the act of infringement shall extend to any patent that claims the biological product, a method of using the biological product, or a method or product used to manufacture the biological product.''; and (2) by adding at the end the following: ``(7)(A) Subject to subparagraphs (C), (D), and (E), if the sponsor of an approved application for a reference product, as defined in section 351(i) of the Public Health Service Act (42 U.S.C.…





